A failed cytotoxicity test can raise red flags for medical device development. To pinpoint the culprit, analyze the test media from the failed test. By tracing the analysis back to the bill of materials (BOM) and processing aids, the specific component responsible can often be identified. If the identified compound poses no toxicological risk in the intended application, this trace analysis can provide justification for releasing the product.